N/A
Manufactured by Bayer HealthCare Pharmaceuticals Inc.
36,175 FDA adverse event reports analyzed
Last updated: 2026-04-14
INTERFERON BETA 1B is a medication tracked in the FDA Adverse Event Reporting System (FAERS), manufactured by Bayer HealthCare Pharmaceuticals Inc.. The most commonly reported adverse reactions for INTERFERON BETA 1B include INFLUENZA LIKE ILLNESS, MULTIPLE SCLEROSIS RELAPSE, INJECTION SITE PAIN, FATIGUE, MULTIPLE SCLEROSIS. This page provides a comprehensive breakdown of reported side effects, safety signals, patient demographics, and AI-powered safety analysis for INTERFERON BETA 1B.
Out of 18,965 classified reports for INTERFERON BETA 1B:
The FDA classifies an adverse event as “serious” if it results in death, hospitalization, disability, congenital anomaly, or requires intervention to prevent permanent damage.
Demographics reflect voluntary FDA adverse event reporting patterns and may not represent the full patient population.
This profile reflects 36,175 FDA FAERS reports that mention INTERFERON BETA 1B. Reporting is voluntary and does not prove that the drug caused any listed event.
Frequently reported terms in FAERS include INFLUENZA LIKE ILLNESS, MULTIPLE SCLEROSIS RELAPSE, INJECTION SITE PAIN, FATIGUE, MULTIPLE SCLEROSIS, INJECTION SITE ERYTHEMA. Rankings reflect reporting volume in this dataset, not confirmed side effect rates in the general population.
Labeling and FAERS entries often list Bayer HealthCare Pharmaceuticals Inc. in connection with INTERFERON BETA 1B. Always verify the specific product and NDC with your pharmacist.